Clinical UM Guideline

This document addresses the use of the following ablative techniques for treating Barrett’s esophagus (BE): radiofrequency ablation, cryoablation, laser ablation, argon plasma coagulation, and electrocoagulation.

Note: Please see the following related document for additional information:

• CG-MED-59 Upper Gastrointestinal Endoscopy in Adults

Medically Necessary:

I.  High grade dysplasia (HG) or Intramucosal cancer (IMC):

Ablative treatment of Barrett’s esophagus is considered medically necessary when the following criterion have been met (A, B, and C):

1. The pathology findings include either of the following:
   1. High grade dysplasia (HG); or
   2. Intramucosal cancer (IMC);
      and
2. The procedure is intended as an alternative to esophagectomy; and
3. Either of the following techniques are used:
   1. Radiofrequency ablation; or
   2. Cryoablation treatment.

II. Low grade dysplasia (LGD):

Ablative treatment of Barrett’s esophagus is considered medically necessary when the following criterion have been met (A, B, and C):

1. The pathology finding is low grade dysplasia (LGD); and
2. The biopsy finding of LGD has been confirmed by two independent physicians*; and
3. Either of the following techniques are used;
   1. Radiofrequency ablation; or
   2. Cryoablation treatment.

*Note: The American Gastroenterological Association recommends that LGD should be confirmed by two pathologists since published studies have reported higher rates of progression of LGD when initial readings have been confirmed by expert pathologists, thereby eliminating or minimizing the rate of false positive diagnoses of LGD.

Not Medically Necessary:

Cryoablation and radiofrequency ablation treatments for Barrett’s esophagus are each considered not medically necessary when the above criteria have not been met, and for all other indications.

The following techniques as ablative treatment for Barrett’s esophagus are considered not medically necessary under all circumstances:

1. Electrocoagulation
2. Laser ablation
3. Argon plasma coagulation.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:

When services are Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met, or for any other type of ablation other than radiofrequency or cryoablation, or for the following diagnosis:

BE is a precancerous condition caused by acid damage to the esophageal epithelium. The presence of BE is associated with an increased risk of developing cancer of the esophagus. Surgical treatment options for BE include esophagectomy and endoscopic mucosal resection.

BE occurs as a result of chronic gastroesophageal acid reflux (GERD), which is characterized by leakage of acidic stomach contents into the esophagus due to a malfunctioning lower esophageal sphincter (LES). GERD affects approximately 20% of the adult population in the United States. Esophageal cancer frequently arises from untreated BE. Once precancerous changes are discovered, the lower esophagus is usually surgically removed, or the abnormal epithelium is endoscopically destroyed. Thermal ablative techniques use heat or cold to destroy abnormal tissue. Thermal ablative techniques include electrocoagulation, argon plasma coagulation, radiofrequency ablation, cryoablation, and laser ablation (neodymium-yttrium aluminum garnet [Nd-YAG] and potassium titanium phosphate [KTP]). Ablation can also be achieved through photochemical injury using a technique called photodynamic therapy.

Radiofrequency Ablation (RFA)

RFA uses radio waves and heat to destroy tissue. A balloon catheter containing many small electrodes is placed into the esophagus during endoscopy. Radiofrequency energy is delivered after the balloon is inflated. Literature published when RFA was emerging as a treatment for BE included sham-controlled trials and randomized trials which showed the less invasive technique was effective at reducing risk of disease progression with decreased risk compared with invasive surgical procedures (Haidry, 2015; Phoa, 2014; Shaheen, 2009).

Cotton (2017) reported the results from a 5-year follow-up analysis that aimed to evaluate the recurrence of BE in prospectively followed individuals who achieved complete eradication of intestinal metaplasia (CEIM) after RFA as part of a randomized sham-controlled trial. Of 119 individuals, 110 (92%) achieved CEIM. Recurrence of BE or dysplasia after CEIM occurred in 35 of 110 individuals (32%) and of the 35 occurrences, 24 (75%) occurred in the first year. While there was greater probability of recurrence in the first year, neither BE nor dysplasia recurred at a constant rate. The authors concluded that individuals who remained free of BE or dysplasia in the first year after RFA had a low risk of recurrence.

Two retrospective cohort studies were released in 2017 that assessed the recurrence of BE, metaplasia, and dysplasia after RFA. Guthikonda reported that of 306 individuals, 218 (71%) achieved CEIM. Of these 218 individuals, 52 (24%) had recurrence of BE or metaplasia over 540.6 person-years. Second CEIM was achieved in 30 of those 52 individuals (58%) and 4 individuals (1.8% of total, 7.7% of recurrences) progressed to invasive adenocarcinoma. The authors concluded that in individuals with recurrent BE, RFA helps most individuals achieve second CEIM. Kahn divided 173 individuals into one group of 79 individuals (45.7%) who received RFA and another group of 94 individuals (54.3%) who underwent surveillance. After RFA, 7 individuals (8.9%) progressed to HGD or adenocarcinoma compared to 14 individuals (14.9%) undergoing surveillance (p=0.44). The authors concluded that RFA of BE with LGD does not significantly reduce HGD or adenocarcinoma when compared to surveillance.

In 2018, Pandey published a systematic review and meta-analysis that evaluated the efficacy of RFA in individuals with LGD. The literature search yielded two randomized controlled trials and six observational cohort studies. The studies included a total of 619 individuals with LGD (RFA=404, surveillance=215). Primary outcome measures included the rates of CEIM and complete eradication of dysplasia (CE-D). Secondary outcome measures included the recurrence of dysplasia, the rates of progression to HGD or cancer, and adverse events. Follow-up for the eight studies ranged from 12 to 44 months with a median of 26 months. The data showed the overall pooled rates of CEIM and CE-D after RFA were 88.17% (95% confidence interval [CI], 88.13%-88.20%; p<0.001) and 96.69% (95% CI, 96.67%-96.71%; p<0.001), respectively. RFA had significantly lower rates of progression to HGD or cancer when compared with surveillance (odds ratio [OR] 0.07; 95% CI, 0.02-0.22). The pooled recurrence rates of intestinal metaplasia and dysplasia were 5.6% (95% CI, 5.57-5.63; p<0.001) and 9.66% (95% CI, 9.61-9.71; p<0.001). While this study shows positive short-term safety and efficacy outcomes in the use of RFA in individuals with LGD, there are several limitations including the potential for selection bias in the included retrospective studies and short-term evaluation in all included studies.

In 2020, Alves published a systematic review evaluating diagnosis, treatment, and follow-up of BE. A total of 26 studies specifically addressed treatment, with the majority discussing ablative endoscopic therapies. In comparison, endoscopic resection had higher levels of complications than radiofrequency ablation (24% versus 0%, p=0.02) and required a higher number of therapeutic sessions (6 [1-20] versus 3 [1-8], p=0.00). Other treatment modalities such as argon plasma coagulation did not demonstrate non-inferiority in comparison to radiofrequency ablation. The authors conclude that radiofrequency ablation is the preferred minimally invasive technique for treatment of BE.

In 2021 White reported on a prospective, non-randomized trial involving 239 individuals with BE or IMC treated with RFA. The median number of ablation sessions was 3 (range 1-9), and other ablative techniques were used to eradicate small areas of BE in 104 (43.5%) individuals. Argon plasma coagulation was used in the majority of cases (39%) followed by excision biopsy (4%). Resection of metachronous lesions during the initial RFA treatment was required in 13% of individuals. The authors reported a complete remission of intestinal metaplasia (CR-IM) rate of 89.8%, and a complete remission of dysplasia (CR-D) rate of 90.4%. Complete remission was not achieved in 6.7% individuals, primarily due to RFA failure, defined as no endoscopic change in Barrett’s length after three sessions, or abandonment. CR-IM/CR-D was achieved in 150 individuals. A total of 6 individuals (4%) died in the first 5 years of follow up, all from non-tumor-related causes. The 5-year survival rate was 91.9%. During the 15-year follow-up of the study, the overall survival rate was 82% with a median follow up of 38 months (14-60) post CR-IM/CR-D. Recurrence of dysplasia defined as HGD or adenocarcinoma, was detected in 7 individuals (4.7%) after CR-D. The median time for recurrence was 14.9 months. No perforations related to RFA were reported, bleeding rate was 0.8%, and stricture rate requiring therapeutic dilatation was 5.4%. The authors concluded that BE endotherapy is minimally invasive, effective, and safe. The data from this longitudinal study provides evidence demonstrating significant long-term health-related outcomes for RFA treatment for BE.

Kobayashi (2021) reported results of a case series study involving 433 individuals with BE who were treated with resection and/or RFA. A total of 381 (88%) achieved complete eradication of neoplasia (CE-N). Adequate follow-up was available for 345 (80%) and were included in the analysis. Of that population, a total of 266 (77%) individuals achieved CE-IM at a median follow-up of 45.9 months. Recurrent dysplasia was reported in 20 individuals (5.8%) after achieving CE-N. Survival analysis indicated that time free of recurrence in those who achieved CE-IM was significantly higher than those that did not achieve CE-IM (p=0.002). CE-IM was also associated with a significantly lower hazard of recurrence (HR, 0.2). The number of endoscopic treatments to achieve CE-N was associated with a significantly higher hazard of recurrence (HR,1.1). The authors concluded that, “Achieving CE-IM following CE-N reduces the risk of recurrent dysplasia and should be considered a treatment target among patients with BE undergoing endoscopic therapies.”

Wolfson (2022) reported on the long-term durability of RFA for BE in a prospective study involving data from 2535 individuals. The 10-year Kaplan Meier cancer rate was 4.1% with a crude incidence rate of 0.52 per 100 individual years. After 2 years CR-D was 88% and CR-IM was 62.6%; at 8 years, Kaplan Meier relapse rates were 5.9% from CR-D and 18.7% from CR-IM. Most relapses occurred within the first 2 years (2.7%). The authors reported that endoscopic mucosal resection before RFA increased the likelihood of rescue resection from 17.2% to 41.7%, but did not affect the rate of CR-D, whereas rescue resection after RFA reduced CR-D from 91.4% to 79.7% (p<0.001). The authors concluded that “RFA treatment is effective and durable to prevent esophageal adenocarcinoma.”

Knabe (2023) published a prospective randomized trial that compared simplified RFA (defined as a protocol of 3×12 J/cm2 with focal 90° catheter balloon using 2×10 J/cm2) to hybrid argon plasma coagulation in the treatment of individuals with BE. Hybrid coagulation was defined as injection of saline into the submucosal layer prior to ablation at 60 W. Inclusion criteria were individuals aged 18-99 with eradication of neoplastic BE following endoscopic resection, a planned complete eradication or primary ablation for low-grade neoplasia or macroscopically invisible high-grade neoplasia, and BE length ≥ 1 cm by Prague classification. Exclusion criteria were individuals with no history of neoplasia, individuals in whom complete BE eradication was not planned, prior ablation therapy, high-grade strictures after endoscopic resection that were deemed unsuitable for multiple dilation treatment, other non-curatively treated cancers, a severe comorbidity, or less than 1 year life expectancy. After endoscopic resection, 101 individuals were assigned to either hybrid argon plasma coagulation (H-APC [n=54]) or RFA (n=47) treatment arms. The primary outcomes measured were eradication rates and adverse events. Follow-up exams occurred at 3, 6, 12 and 24 months. After 211 ablations were performed, eradication rates at 21 months were 74.2% in the RFA group and 82.9% in the H-APC group. Stenoses that required intervention occurred in 3.7% of individuals in the H-APC group and 14.9% in the RFA group. Adverse events included 1 case of acute bleeding that required treatment, 1 individual who developed a fever after H-APC, and 1 individual who was admitted for gastrointestinal hemorrhage. No perforations occurred in the study participants. Only 26.7% of participants completed the full study protocol. The authors attributed this to a lack of follow-up resulting from the Covid-19 pandemic. The authors concluded that eradication rates were similar between groups, however, the complication rate, specifically the stricture rate, favor H-APC for treatment after endoscopic resection. The authors also noted that differences in stenosis rates were significant and further stated that the simplified RFA protocol is no longer recommended by the device manufacturer. This study is limited by its small size and significant loss to follow up. Additionally, the comparator treatment (simplified RFA) is no longer recommended. More robustly powered studies with long-term follow-up that compare traditional RFA to H-APC are needed to determine whether H-APC treatment is non-inferior to RFA, and to further assess long-term health-related outcomes of this ablative treatment for individuals with BE.

In 2011, the American Gastroenterological Association (AGA) released its medical position statement on the management of BE. They noted difficulty in distinguishing an accurate degree of dysplasia (low-grade, high-grade, or nondysplastic BE) due to the architecture and aberrancies of the esophagus and that there are no well-defined cut-off points that separate LGD from HGD. The risk of progression from LGD to HGD or adenocarcinoma is not well-known and varied greatly between studies. Rates of progression have been reported as low as 0.22% per year (Bhat, 2011) and as high as 13.4% (AGA, 2011). Despite variations in determining the risk of progression from LGD to HGD, the AGA report concludes that radiofrequency ablation should be a therapeutic option for those with confirmed LGD in BE. Radiofrequency ablative therapy for those individuals with BE with LGD leads to reversion to normal-appearing squamous epithelium in greater than 90% of cases and the reversion can persist for up to 5 years.

Additionally, the AGA published a clinical practice update on endoscopic treatment of BE (Sharma, 2020). The update regarding endoscopic ablative BE therapy states the following:

Given the presence of level I evidence documenting superiority over endoscopic surveillance and the large number of publications documenting efficacy in a variety of treatment settings, societal guidelines recommend RFA as first-line therapy for ablation of flat-type dysplastic BE or BE after resection of visible lesions.

In 2022, the American College of Gastroenterology also recommended endoscopic ablative therapy for individuals with BE (Shaheen, 2022):

17. We recommend endoscopic eradication therapy in patients with BE with HGD or IMC. Quality of evidence Moderate, Strength of recommendation: Strong
18. We suggest endoscopic eradication therapy in patients with BE with LGD to reduce the risk of progression to HGD or EAC vs close endoscopic surveillance. Quality of evidence Moderate, Strength of recommendation: Conditional
19. We suggest initial endoscopic resection of any visible lesions before the application of ablative therapy in patients with BE undergoing endoscopic eradication therapy. Quality of evidence Very low, Strength of recommendation: Conditional

In 2024, the AGA published a clinical practice guideline on endoscopic eradication therapy (EET) of BE and related neoplasia. The guideline includes the following recommendations:

1. In individuals with BE with HGD, the AGA recommends EET over surveillance. (Strong recommendation, moderate certainty of evidence.)
2. In individuals with BE with LGD, the AGA recommends EET over surveillance. (Conditional recommendation, low certainty of evidence.)
3. In individuals with nondysplastic Barrett’s esophagus (NDBE), the AGA suggests against the routine use of EET. (Conditional recommendation, very low certainty of evidence.)
4. In patients undergoing EET, the AGA suggests resection of visible lesions followed by ablation of the remaining BE segment over resection of the entire BE segment. (Conditional recommendation, very low certainty of evidence.)
5. In individuals with BE with visible neoplastic lesions that are undergoing endoscopic resection, the AGA suggest the use of either endoscopic mucosal resection or endoscopic submucosal dissection based on lesion characteristics. (Conditional recommendation, very low certainty of evidence.)

The National Comprehensive Cancer Network^® (NCCN^®) Clinical Practice Guideline (CPG) for esophageal and esophagogastric junction cancers (V1.2025) addresses treatment of BE in the following statement:

The goal of endoscopic therapy [by endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and/or ablation] is the complete removal or eradication of early-stage disease (pTis, pT1a, selected superficial pT1b without LVI) and pre-neoplastic tissue (Barrett’s esophagus).

If HGD is confirmed, patients should be managed with endoscopic therapy unless they have a life-limiting comorbidity.

The updated NCCN^® CPG for esophageal and esophagogastric junction cancers (Version 1.2025), notes that for adenocarcinoma of the esophagus, endoscopic resection followed by ablation may be used to completely eliminate residual dysplasia or Barrett epithelium.

Cryoablation

Cryoablation is another treatment for BE. This involves the administration of a cryogen, which is a liquefied gas such as nitrogen or carbon dioxide, during endoscopy to freeze and destroy the diseased tissue (ASGE, 2017). Early literature including pilot studies, prospective studies, and retrospective analyses addressed the use of cryoablation for BE (Dumont, 2009; Greenwald, 2010; Johnston, 2005; Shaheen, 2010). Though there were flaws and biases noted, the authors reported positive results in the treatment of BE with HGD, LGD, and IMC.

In 2017, Künzli published a prospective trial to study the efficacy and performance of cryoablation in individuals with flat dysplastic BE. Out of 30 individuals enrolled in the trial, 29 completed the trial with a total of 42 of the 44 identified BE areas (95%) being fully eradicated of intestinal metaplasia and dysplasia. Some limitations of this study include inclusion of individuals with previous treatment with RFA, a small sample size, the lack of randomization, and a lack of controls. The authors note that the extent of the treated BE areas were limited and further research is needed in cryoablation and individuals with more extensive BE segments.

In 2018, Visrodia reported on a systematic review and meta-analysis that evaluated the efficacy of second-line cryoablation in individuals with BE who have persistent dysplasia or intestinal metaplasia after RFA. The literature search yielded 11 studies with a total of 148 participants. Of the 11 studies, 7 were retrospective, 3 were prospective, and 1 did not report the study design. The number of individuals enrolled in each study ranged from 5 individuals to 47 individuals. Two of the studies were multicenter, and 9 of the studies were conducted at single centers. The authors found “the pooled proportion of CE-D was 76.0% (95% CI, 57.7-88.0), with substantial heterogeneity (I² = 62%). The pooled proportion of complete eradication of intestinal metaplasia (CE-IM) was 45.9% (95% CI, 32.0-60.5) with moderate heterogeneity (I² = 57%). Multiple preplanned subgroup analyses did not sufficiently explain the heterogeneity” (Visrodia, 2018). These results suggest that cryoablation is a viable second-line option in individuals with BE who have persistent dysplasia or intestinal metaplasia after RFA.

In 2019, Mohan published a systematic review and meta-analysis on cryoablation. The authors aimed to assess the overall efficacy and safety of cryoablation using liquid nitrogen as a treatment option for BE. A total of nine studies with 386 participants were included in the final meta-analysis. There were six retrospective studies and three prospective studies with the number of participants ranging from 16 to 81. Four studies were conducted at a single center and five studies were multicenter. The authors found that “the pooled rate of CE-IM was 56.5% (95% CI, 48.5-64.2, I² = 47), pooled rate of complete eradication of intestinal dysplasia (CE-D) was 83.5% (95% CI, 78.3-87.7, I² = 22.8), and pooled rate of complete eradication of high grade dysplasia CE-HGD was 86.5% (95% CI, 64.4-95.8, I² = 88.1). The rate of adverse events was 4.7%, and the risk of BE recurrence was 12.7%” (Mohan, 2019). The findings of this meta-analysis show positive results with a low risk of adverse events for cryoablation using liquid nitrogen as a treatment option for BE .

In 2020, Westerveld reported the results of a systematic review and meta-analysis on the safety and effectiveness of balloon cryoablation for treatment of BE. The authors found four prospective studies and three retrospective studies with a total of 548 ablation sessions in 272 individuals for inclusion in the meta-analysis. Data showed a pooled rate of technical success (completing ablation as planned) at 95.8% (95% CI: 93.6-97.5%; I²=13.2%; p=0.3), CE-IM at 85.8% (95% CI: 77.8-92.2 %, I²=55.5%; p=0.04), and CE-D at 93.8% (95% CI: 85.5-98.7 %, I²=74.2%; p=0.001). There were 34 (12.5% of individuals) post-procedural adverse events. While this study had several limitations, including lack of large randomized controlled trials, the high rates of CE-IM and CE-D along with a comparable safety profile to spray cryoablation and RFA show balloon cryoablation is an effective treatment strategy for BE.

In 2020, Canto published a prospective clinical trial evaluating cryoballoon ablation for eradication of BE. A total of 94 individuals were enrolled and completed cryoballoon ablation. CD-D was achieved in 91/94 individuals (97%) and CE-IM occurred in 86/94 individuals (91%). There were 3 individuals who required RFA due to difficulty positioning the balloon or due to repeated balloon deflation. A single individual progressed to neoplasm and required additional treatments. There were no serious adverse events directly related to the procedure, though 1 individual developed a mucosal laceration related to balloon trauma. Cryoballoon ablation showed low rates of postprocedural bleeding and hospitalization. These rates were similar to those observed for RFA. Cryoballoon ablation for individuals that have not undergone previous ablative techniques showed positive results and was well tolerated.

Fasullo (2021) reported the results of a retrospective comparative trial involving 162 individuals with BE who underwent treatment for BE with either RFA (n=100) or cryoablation with liquid nitrogen spray cryotherapy (n=62). The authors reported that the most common reasons listed in the medical record for choosing cryoablation instead of RFA. Individual preference was the most frequent (82.4%) reason followed by use of anticoagulation (6.5%) and an alternative to esophagectomy for multi-nodular BE (6.5%). CE-D within 4 ablation sessions was achieved in 77% of individuals and CE-IM in 65%, with no significant difference between the RFA group and cryo groups (81% vs. 71.0%, respectively, p=0.14). The number of sessions required to achieve CE-D was higher in the cryo group compared to the RFA group (4.2 vs. 3.2, p=0.05). Switching procedure types occurred in 15% of individuals who initially underwent RFA and 24% of those that initially received cryotherapy. The most common reason reported for switching was treatment failure, followed by intolerance to initial procedure. No differences between the switching groups were noted with regard to CE-D (p=0.67). Recurrent dysplasia occurred in 11% of RFA and 14% of cryoablation-treated individuals (p=0.52). The likelihood of developing recurrent dysplasia was higher among individuals who did not achieve CE-IM (12%) compared to those who did (4%, p=0.04). No data was provided regarding adverse events. The authors concluded that the two procedures were “equally effective at eradicating dysplasia and IM. Similarly, long-term remission rates were similar regardless of the ablation modality initially selected.”

Gomes (2024) conducted a systematic review and meta-analysis of three studies comparing RFA and cryotherapy for treating dysplastic BE, with or without early esophageal neoplasia (n=627). The review included adults with BE and histological evidence of LGD, HGD, or IM, and compared several outcomes after RFA or cryotherapy, including: CE-IM and CE-D, adverse events, and recurrence rates. Studies were excluded if they reported non-histopathological BE eradication rates or did not report post-treatment surveillance endoscopy. The meta-analysis found no significant differences between RFA and cryotherapy in CE-IM (95% CI, -0.25 to 0.19; p=0.78), CE-D (95% CI, -0.15 to 0.09; p=0.64), recurrence rates (95% CI, -0.02 to 0.19; p=0.12), or adverse events (10 strictures with RFA, 9 with cryotherapy, no perforations or bleeding). The GRADE analysis indicated a very low certainty of evidence. The authors concluded both treatments were equally effective with no difference in recurrence rates, but the findings were limited by the retrospective cohort study design and very low certainty of evidence. Additional studies, including RCTs, are needed to confirm this study’s findings.

Laser Ablation
Laser ablation uses high-intensity light to treat cancer. For the esophagus, Nd:YAG lasers are applied through an endoscope and the light is precisely aimed at the diseased tissue, which is destroyed.

Weston (2002) reported on the safety and efficacy of laser ablation of BE and HGD. Seventeen participants received laser ablation therapy for high-grade dysplasia. Three participants exited the study. Of the 14 participants who remained in the study, all had successful eradication of their HGD and/or cancer. Eleven participants achieved histologic and endoscopic ablation of all Barrett’s esophageal tissue. Seven of the 11 participants with complete ablation had subsequent follow-up ranging from 2-36 months. Four of the 7 participants demonstrated regrowth, 2 were successfully treated with an electrosurgical generator and 2 were successfully treated with laser ablation. While treatment appears promising, the authors conclude “there is a need for additional controlled trials with a larger number of patients and longer follow-up, as well as for consideration of a head-to-head trial with Photofrin PDT.”

Argon Plasma Coagulation

Argon plasma coagulation is a non-contact thermal method of delivering an electrical current by way of argon gas to the targeted tissue. The argon gas flows through a catheter that is passed through an endoscope. A spark ionizes the argon gas as it is sprayed from the tip of the catheter in the direction of the targeted tissue. This produces tissue coagulation and can be used to treat large surface areas.

In 2007, Mork reported on 25 individuals who received argon plasma coagulation and a proton-pump inhibitor prior to and following the ablation procedure. The individuals received endoscopic surveillance following complete eradication of the glandular epithelium and continuing for 51 months with recurrence of BE detected in 14 of the 25 individuals. This study demonstrated a relapse rate of approximately two-thirds after argon plasma eradication of BE. Success rates may be dependent on the amount of thermal energy applied and the proton pump inhibitor schedule. Higher energy may carry more risks, but no standards have been established for this procedure yet.

Formentini (2007) reported on a retrospective analysis of the efficacy of ablation of BE using argon plasma coagulation followed by fundoplication. Twenty-one individuals met study criteria. All individuals received argon plasma coagulation treatments approximately every 4-6 weeks until the metaplastic epithelium was ablated. Then all individuals underwent Nissen fundoplication. Response to treatment was measured every 6-12 months. Recurrence of BE was observed in 6 of the 17 participants. Five of the 6 participants had ablation by argon plasma coagulation (1 participant refused) and were disease-free at the time of publication. The authors stated that “further studies are required to clarify the role of ablation’s procedure in the treatment of BE.”

Bright (2009) reported on a randomized controlled trial which compared 57 participants with BE who underwent argon plasma coagulation or were followed with annual endoscopic surveillance. Annual biopsies were examined by a treatment blinded pathologist (argon plasma coagulation or surveillance). At 12 months, 14 out of 23 participants who had received argon plasma coagulation showed at least 95% ablation of the metaplastic mucosa and 9 participants had complete regression of BE. None of the individuals who had surveillance endoscopy had more than 95% regression. While these results look promising, ablation with argon plasma coagulation is more time-consuming than routine surveillance endoscopy, participants who have had argon plasma coagulation still need endoscopic surveillance and in this particular study, at least some of the metaplastic columnar mucosa recurred during the first 12 months. It is not possible to predict which individuals will have recurrence and the outcomes at 12 months were not as good as immediately following the treatment. The authors have concluded that argon plasma coagulation “should probably remain within clinical trials.”

Manner (2014) reported results for 63 participants who had been curatively resected of Barrett’s neoplasia by endoscopy and were randomized to receive either argon plasma coagulation (n=33) or surveillance only (n=30). The primary outcome was recurrence-free survival. During the follow-up period of 2 years, 1 secondary lesion was found in the ablation group and 11 secondary lesions were found in the surveillance group. While the results showed fewer secondary lesions following argon plasma coagulation, this study was limited by its small group size and according to the authors a “limited follow-up of 2 years.”

Shimizu (2012) reported the results of a case series study of 22 individuals with BE who were treated with argon plasma coagulation (40 overall treatments). Both treatment naïve and previously treated individuals were included. Mean follow-up was 134.7 days. Complete resolution of intestinal metaplasia was achieved in 19 of 22 individuals (86.4%) according to histopathology (12 had one procedure, 2 had two procedures, 1 had three procedures, and 4 had four treatment procedures). Three individuals did not achieve complete resolution of intestinal metaplasia. Treatment-related strictures requiring balloon dilation occurred in 2 individuals (9.1%). No bleeding or perforation events were reported. This study was limited by its small group size, lack of a control group, and limited follow-up.

Knabe (2022) reported the results of a prospective case series study involving 154 individuals with BE treated with hybrid argon plasma coagulation, which consists of argon plasma coagulation following curative endoscopic resection of visible neoplastic lesions. A total of 148 individuals completed the study’s 2-year follow-up period.

The primary outcome of treatment success was reported for 83.7% (129/154) of the participants in the intention to treat (ITT) analysis. No recurrence was reported in 85 individuals, indicating a successful treatment rate of 65.9% in the ITT population and 70.8% in the per-protocol (PP) analysis. A mean of 2.69 ablation sessions (range 1-5) were reported in the 148 individuals with completed or attempted therapy within the protocol. A total of 17 individuals were considered treatment failures. The 2-year recurrence rate was reported to be 34.1% in the ITT analysis and 29.2% in the PP analysis. For combined resection and ablation therapy, CE-IM was reached in 65.9% of cases in the PP analysis and CE-N was reported in 97.7%. The rate of remaining BE-free at 2 years was 55.2%. The complication rate was 0.5% per procedure session and 6.1% per individual. Two of these complications, major bleeding and perforation (n=1 each) were considered significant. Post-procedure stricture was reported in 3.9% of individuals and odynophagia in 10.4%. The authors concluded, “Eradication and recurrence rates of Barrett’s intestinal metaplasia and neoplasia by means of hybrid argon plasma coagulation at 2 years seem to be within expected ranges. Final evidence in comparison to RFA can only be provided by a randomized comparative trial.” While this study had reasonable study population and follow-up, the lack of control group prevents conclusions being drawn about the effects of argon plasma coagulation compared to RFA. As noted by the authors, an RCT would be helpful to fully evaluate the clinical utility of the hybrid argon plasma coagulation procedure.

Kozyk (2024) conducted a systematic review and meta-analysis of 38 studies evaluating the safety and efficacy of argon plasma coagulation for managing Barrett's Esophagus (BE). The inclusion criteria covered prospective and retrospective studies of individuals with BE, with or without dysplasia, treated with argon plasma coagulation. Outcomes measured included the clearance rates of intestinal metaplasia, adverse events, and recurrence rates. The study found that the pooled clearance rate of intestinal metaplasia was 86.8% (95% CI, 83.5% to 90.2%), with high-power and hybrid argon plasma coagulation demonstrating higher rates compared to standard argon plasma coagulation. The pooled incidence of adverse events was 22.5% (95% CI, 15.3% to 29.7%), with self-limited chest pain being the most common. Serious adverse events were rare at 0.4% (95% CI, 0.0% to 1.0%). Stricture development occurred in 1.7% (95% CI, 0.9% to 2.6%) of cases. The pooled recurrence rate of BE was 16.1% (95% CI, 10.7% to 21.6%), with lower recurrence seen in high-power argon plasma coagulation compared to standard. The authors concluded that high-power and hybrid argon plasma coagulation provide better clearance and reduced recurrence rates than standard argon plasma coagulation. Additional studies are necessary to compare the efficacy and safety of hybrid argon plasma coagulation to the safety and efficacy of standard argon plasma coagulation and RFA .

Electrocoagulation

Electrocoagulation uses a fine wire probe to deliver radio waves to tissues near the probe. The radio waves cause the tissue to vibrate which increases temperature causing coagulation and destruction of the tissue. Electrocoagulation can be either monopolar or bipolar. For individuals with an implantable device such as a pacemaker or automatic defibrillator, bipolar is the preferred method because the electrical current does not travel beyond the depth of thermal injury and disrupt the programming of these devices. There is minimal literature published for electrocoagulation for use in BE. In 1999, Sharma and colleagues reported on 6 individuals with BE who received laser treatment and electrocoagulation. The number of electrocoagulation sessions ranged from 1-5.

Follow-up ranged from 9-86 months. Complete ablation was achieved. The authors concluded “Despite the success achieved in this group of patients, the use of such therapy as an alternative to surgery in all patients with early Barrett’s cancer is not currently recommended.”

Other Considerations

The American College of Gastroenterology, the American Gastroenterological Association, and the American Society of Gastrointestinal Endoscopy do not have guidelines or position statements endorsing laser ablation, argon plasma ablation or electrocoagulation as a treatment for BE. Current literature consists primarily of uncontrolled, small studies, with only a limited number of randomized controlled trials comparing treatments for BE. Few long-term results are available (Li, 2008). The authors of a Cochrane review in 2010 concluded that ablative therapies have a role in the management of BE, however; “more clinical trial data and in particular randomized controlled trials are required to assess whether or not the cancer risk is reduced in routine clinical practice.”

The American Society for Gastrointestinal Endoscopy (ASGE, Wani, 2018) published guidelines on endoscopic eradication therapy (EET) for individuals with BE-associated dysplasia and IMC. The ASGE states EET “entails endoscopic mucosal resection (EMR) of visible lesions within the Barrett’s segment and ablative techniques that include radiofrequency ablation (RFA) and cryotherapy”. The following is a summary of the ASGE recommendations:

• In Barrett’s esophagus patients with LGD and HGD being considered for EET, we suggest confirmation of diagnosis by at least 1 expert GI pathologist or panel of pathologists compared with review by a single pathologist (Strength of recommendation: Conditional; Quality of evidence: Low).
• In Barrett’s esophagus patients with LGD, we suggest EET compared with surveillance; however, patients who place a high value on avoiding adverse events related to EET may choose surveillance as the preferred option (Strength of recommendation: Conditional; Quality of evidence: Moderate).
• In Barrett’s esophagus patients with confirmed HGD, we recommend EET compared with surveillance (Strength of recommendation: Strong; Quality of evidence: Moderate).
• In Barrett’s esophagus patients with HGD/IMC, we recommend against surgery compared with EET (Strength of recommendation: Strong; Quality of evidence: Very low quality evidence).
• In Barrett’s esophagus patients referred for EET, we recommend endoscopic resection of all visible lesions compared with no endoscopic resection of visible lesions (Strength of recommendation: Strong; Quality of evidence: Moderate).
• In Barrett’s esophagus patients with visible lesions who undergo endoscopic resection, we suggest ablation of the remaining Barrett’s segment compared with no ablation (Strength of recommendation: Conditional; Quality of evidence: Low).
• In Barrett’s esophagus patients with dysplasia and IMC referred for EET, we recommend against routine complete endoscopic resection of entire Barrett’s segment compared with endoscopic resection of visible lesion followed by ablation of remaining Barrett’s segment (Strength of recommendation: Strong; Quality of evidence: Very low).
• In Barrett’s esophagus patients with dysplasia and IMC who have achieved CEIM after EET, we suggest surveillance endoscopy versus no surveillance (Strength of recommendation: Conditional; Quality of evidence: Very low).

Argon plasma coagulation: A non-contact thermal technique which uses ionized argon gas to deliver a high-frequency current which coagulates tissue.

Barrett's esophagus (BE): A complication due to chronic severe gastroesophageal reflux disease (GERD), in which the cells that line the esophagus near the stomach become pre-cancerous; resulting in an increased risk of cancer of the esophagus (adenocarcinoma).

Cryoablation: A technique which removes cancerous tissue by killing it with extreme cold.

Electrocoagulation: The use of thermal energy to destroy abnormal tissue.

Endoscopic mucosal resection (EMR): A surgical technique in which fluid is injected into the submucosa, (the layer of the gastrointestinal tract immediately below the mucosa), to elevate the mucosa and allow it to be grabbed with a snare.

Endoscopic submucosal dissection (ESD): A minimally invasive procedure to remove large or complex lesions, such as early-stage tumors or precancerous growths. Unlike traditional endoscopic techniques, it enables removal of the entire lesion in one piece (en bloc) which helps preserve organ structure and function.

Esophageal adenocarcinoma: A cancer that has progressed beyond the mucosal layer and invaded deeper tissues of the esophagus, it is a more advanced stage of cancer compared to HGD and IMC.

Esophagectomy: The surgical removal of a portion of the esophagus; the remaining esophagus is reattached to the stomach so the individual can still swallow.

Gastroesophageal reflux disease (GERD): A disorder caused by the improper functioning of the lower esophageal sphincter, allowing stomach acid or bile to irritate the esophagus lining. Complications of GERD can include esophagitis, BE, and an increased risk of esophageal cancer.

High-grade dysplasia (HGD): Precancerous changes in the cells lining the esophagus that show significant abnormalities and have a high potential to progress to cancer. HGD is considered a precursor to esophageal adenocarcinoma.

Intramucosal cancer (IMC): An early-stage cancer where cancerous cells have invaded the mucosal layer of the esophagus but have not yet penetrated deeper layers. IMC is more advanced than HGD.

Laser ablation: The use of high intensity light to treat cancer and other illnesses.

Low-grade dysplasia (LGD): Early precancerous changes in the esophagus lining. While less likely than HGD to progress to cancer, LGD indicates an increased risk of esophageal adenocarcinoma. Diagnosis is typically made through endoscopic examination and biopsy.

Neoplastic lesion(s): A condition where the normal tissue lining the esophagus is replaced with intestinal-type tissue due to chronic acid exposure. The visible lesions may show changes that indicate early-stage cancer or precancerous growths. In individuals with BE the lesions can progress to esophageal adenocarcinoma.

Nondysplastic Barrett's esophagus (NDBE): A condition where the normal squamous cells of the esophagus are replaced with columnar cells due to chronic GERD, but without any precancerous changes. The risk of progressing to esophageal adenocarcinoma is lower compared to BE with dysplasia.

Peer Reviewed Publications:

1. Alves JR, Graffunder FP, Rech JVT, et al. Diagnosis, treatment and follow-up of Barrett’s esophagus: a systematic review. Arq Gastroenterol. 2020; 57(3):289-295.
2. Beaumont H, Gondrie JJ, McMahon BP, et al. Stepwise radiofrequency ablation of Barrett's esophagus preserves esophageal inner diameter, compliance, and motility. Endoscopy. 2009; 41(1):2-8.
3. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011; 103(13):1049-1057.
4. Birkmyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002; 346(15):1128-1137.
5. Bright T, Watson DI, Tam W, et al. Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication. Dig Dis Sci. 2009; 54(12):2606-2611.
6. Canto MI, Trindade AJ, Abrams J, et al. Multifocal cryoballoon ablation for eradication of Barrett's esophagus-related neoplasia: a prospective multicenter clinical trial. Am J Gastroenterol. 2020; 115(11):1879-1890.
7. Cotton CC, Wolf WA, Overholt BF, et al. Late recurrence of Barrett’s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology. 2017; 153(3):681-688.e2.
8. Dumot JA, Greenwald BD. Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC's of ablative techniques. Endoscopy. 2008; 40(12):1026-1032.
9. Dumot JA, Vargo JJ 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009; 70(4):635-644.
10. Eldaif SM, Lin E, Singh KA, et al. Radiofrequency ablation of Barrett's esophagus: short-term results. Ann Thorac Surg. 2009; 87(2):405-410.
11. Fasullo M, Shah T, Patel M, et al. Outcomes of radiofrequency ablation compared to liquid nitrogen spray cryotherapy for the eradication of dysplasia in Barrett's Esophagus. Dig Dis Sci. 2022; 67(6):2320-2326.
12. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008; 68(5):867-876.
13. Formentini A, Schwarz A, Straeter J, et al. Treatment of Barrett's esophagus with argon plasma coagulation and antireflux surgery. A retrospective analysis. Hepatogastroenterology. 2007; 54(79):1991-1996.
14. Gomes ILC, de Moura DTH, Ribeiro IB, et al. Cryotherapy versus radiofrequency ablation in the treatment of dysplastic Barrett's esophagus with or without early esophageal neoplasia: a systematic review and meta-analysis. Clin Endosc. 2024; 57(2):181-190.
15. Greenwald BD, Dumot JA, Horwhat JD, et al. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus. 2010; 23(1):13-19.
16. Guthikonda A, Cotton CC, Madanick RD, et al. Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2017; 112(1):87-94.
17. Haidry RJ, Butt MA, Dunn JM, et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's esophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut. 2015; (8):1192-1199.
18. Hubbard N, Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus in patients with fundoplications. Surg Endosc. 2007; 21(4):625-628.
19. Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005; 62(6):842-848.
20. Kahn A, Al-Qaisi M, Kommineni VT, et al. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett’s esophagus with low-grade dysplasia. Dis Esophagus. 2018; 31(4):10.
21. Knabe M, Beyna T, Rösch T, et al. Hybrid APC in combination with resection for the endoscopic treatment of neoplastic Barrett's Esophagus: a prospective, multicenter study. Am J Gastroenterol. 2022; 117(1):110-119.
22. Knabe M, Wetzka J, Welsch L, et al. Radiofrequency ablation versus hybrid argon plasma coagulation in Barrett's esophagus: a prospective randomised trial. Surg Endosc. 2023; 37(10):7803-7811.
23. Kobayashi R, Calo NC, Marcon N, et al. Predictors of recurrence of dysplasia or cancer in patients with dysplastic Barrett's esophagus following complete eradication of dysplasia: a single-center retrospective cohort study. Surg Endosc. 2022; 36(7):5041-5048.
24. Kozyk M, Kumar L, Strubchevska K, et al. Efficacy and safety of argon plasma coagulation for the ablation of Barrett's esophagus: a systemic review and meta-analysis. Gut Liver. 2024; 18(3):434-443.
25. Künzli HT, Schölvinck DW, Meijer SL, et al. Efficacy of the cryoballoon focal ablation system for the eradication of dysplastic Barrett's esophagus islands. Endoscopy. 2017; 49(2):169-175.
26. Li YM, Li L, Yu CH, et al. A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci. 2008; 53(11):2837-2846.
27. Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy. 2014; 46(1):6-12.
28. Mohan BP, Krishnamoorthi R, Ponnada S, et al. Liquid nitrogen spray cryotherapy in treatment of Barrett's esophagus, where do we stand? A systematic review and meta-analysis. Dis Esophagus. 2019; 32(6).
29. Mörk H, Al-Taie O, Berlin F, et al. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol. 2007; 42(1):23-27.
30. Norberto L, Polese L, Angriman I, et al. High-energy laser therapy of Barrett's esophagus: preliminary results. World J Surg. 2004; 28(4):350-354.
31. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; (10):1245-1255.
32. Pandey G, Mulla M, Lewis WG, et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett's esophagus. Endoscopy. 2018; 50(10):953-960.
33. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014; 311(12):1209-1217.
34. Pouw RE, Gondrie JJ, Sondermeijer CM, et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg. 2008; 12(10):1627-1636.
35. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus. 2007; 20(6):516-522.
36. Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc. 2010; 71(4):680-685.
37. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009; 360(22):2277-2288.
38. Sharma P, Jaffe PE, Bhattacharyya A, Sampliner RE. Laser and multipolar electrocoagulation ablation of early Barrett's adenocarcinoma: long-term follow-up. Gastrointest Endosc. 1999; 49(4 Pt 1):442-446.
39. Sharma P, Wani S, Weston AP, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut. 2006; 55(9):1233-1239.
40. Shimizu T, Samarasena JB, Fortinsky KJ, et al. Benefit, tolerance, and safety of hybrid argon plasma coagulation for treatment of Barrett's esophagus: US pilot study. Endosc Int Open. 2021; 9(12):E1870-E1876.
41. Visrodia K, Zakko L, Singh S, et al. Cryotherapy for persistent Barrett's esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc. 2018; 87(6):1396-1404.
42. Westerveld DR, Nguyen K, Banerjee D, et al. Safety and effectiveness of balloon cryoablation for treatment of Barrett's associated neoplasia: systematic review and meta-analysis. Endosc Int Open. 2020; 8(2):E172-E178.
43. Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol. 2002; 97(12):2998-3006.
44. White JR, Ortiz-Fernández-Sordo J, Santiago-García J, et al. Endoscopic management of Barrett's dysplasia and early neoplasia: efficacy, safety and long-term outcomes in a UK tertiary centre. Eur J Gastroenterol Hepatol. 2021; 33(1S Suppl 1):e413-e422.
45. Wolfsen HC. Endoprevention of esophageal cancer: endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices. 2005; 2(6):713-723.
46. Wolfson P, Ho KMA, Wilson A, et al.; UK RFA Study Group. Endoscopic eradication therapy for Barrett's Esophagus related neoplasia. A final 10 year report from the United Kingdom National Halo Radiofrequency Ablation Registry. Gastrointest Endosc. 2022: S0016-5107(22)00121-3.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American Gastroenterological Association, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011; 140(3):1084-1091.
2. ASGE Technology Committee; Parsi MA, Trindade AJ, Bhutani MS, et al. Cryotherapy in gastrointestinal endoscopy. VideoGIE. 2017; 2(5):89-95.
3. NCCN Clinical Practice Guidelines in Oncology®. ©2025 National Comprehensive Cancer Network®, Inc. Esophageal and Esophagogastric Junction Cancers.V1.202F. Revised February 28, 2025. Accessed on March 17, 2025. For additional information visit the NCCN website.
4. Rees JRE, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's esophagus. Cochrane Database Syst Rev. 2013;(6):CD004060.
5. Rubenstein JH, Sawas T, Wani S, et al. AGA clinical practice guideline on endoscopic eradication therapy of Barrett’s esophagus and related neoplasia. Gastroenterology. 2024; 66(6):1020-1055.
6. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's Esophagus: an updated ACG guideline. Am J Gastroenterol. 2022; 117(4):559-587.
7. Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. AGA clinical practice update on endoscopic treatment of Barrett's esophagus with dysplasia and/or early cancer: expert review. Gastroenterology. 2020; 158(3):760-769.
8. Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer: American Society for Gastrointestinal Endoscopy, Standards of Practice Committee. Gastrointest Endosc. 2018; 87(4):907-931.
9. Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low-grade dysplasia in Barrett's esophagus: expert review from the clinical practice updates committee of the American Gastroenterological Association. Gastroenterology. 2016; 151(5):822-835.

Argon plasma coagulation
Barrett’s esophagus
Cryoablation
Electrocoagulation
Laser ablation
Radiofrequency ablation

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only - American Medical Association